Vivos closes Sleep Center of Nevada acquisition for $6M cash + stock; issues $8.25M note

Vivos Therapeutics, Inc.

Acquired operating assets of SCN for $6M cash, 607k restricted shares ($1.5M at VWAP), plus contingent earn-out of up to $1.5M in stock.
Wholly-owned AIM subsidiary signed 15-year PAAs with SCN ($200k/mo fee) and SCN PLLC ($100k/mo fee) to manage practice in compliance with CPM laws.
Issued $8.25M secured promissory note to Streeterville Capital to finance the acquisition; AIM membership interests pledged as collateral.
Integration of two of seven SCN locations underway; deploying 1.5 SO teams currently, targeting 4.5 teams by Q1 2026; patient demand exceeds capacity.
SCN revenue expected in Q2 fiscal 2025; risk factors note unproven model, CPM law compliance, and debt service obligations.

item 9.01item 1.01item 2.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.